| Document |
Document Title |
|
WO/2024/095996A1 |
The purpose of the present invention is to provide an excellent infertility treatment with which it is possible to increase the implantation rate of an embryo (fertilized egg) by improving the uterine environment. The present invention i...
|
|
WO/2024/097851A1 |
Disclosed herein are method for treating an autoimmune or inflammatory disease in a subject that involves administering to the subject a therapeutically effective amount of a composition comprising an antibody that inhibits binding of CD...
|
|
WO/2024/097393A1 |
Provided herein are systems, compositions, and methods for single cell analysis. In particular, provided herein are systems, compositions, and methods for scalable, high-throughput isolation and sequencing of nucleic acids from rare and/...
|
|
WO/2024/073510A3 |
Provided herein are compositions and methods for high-throughput Primary Template-Directed Amplification (PTA) nucleic acid amplification and sequencing methods, and their applications for mutational analysis in research, diagnostics, an...
|
|
WO/2024/093673A1 |
The present application discloses a method for separating a human hair follicle-derived papilla cell. The present application provides a method for separating a hair follicle-derived papilla cell in vitro. The method comprises the follow...
|
|
WO/2024/095251A1 |
The present invention provides a system and a method for editing of an endogenous gene by replacing a gene portion sequence thereof comprised in a single exon with a transgene sequence, the system comprising at least one genome editing r...
|
|
WO/2024/092347A1 |
A cell culture device comprising: a chip component having: a top face and a bottom face, a channel formed in the chip component which is open at the top face and has a base spaced from the bottom face; a well portion extending from the b...
|
|
WO/2024/097051A1 |
The disclosure leverages the therapeutic potential of autologous and allogenic cells, particularly cancer cells and T cells, which have been genetically modified or contacted with specific recombinant proteins, peptides, or nucleic acids...
|
|
WO/2024/097929A1 |
Methods and materials for increasing expression of malic enzyme 1 (ME1) in T cells are provided herein, as are compositions containing ME1 coding sequences or ME1 mRNA, and methods and materials for using T cells with increased ME1 level...
|
|
WO/2024/097864A1 |
The present invention relates to a method for expansion of a population of lymphocytes in a controlled single culture vessel, the method comprising a step of (a) culturing a tissue or blood sample from a subject, which sample is known or...
|
|
WO/2024/077157A3 |
The present disclosure provides for efficient ex vivo processes for generating myeloid cell lineages from human induced pluripotent stem cells (iPSCs). Cells generated according to the disclosure in various embodiments are functional and...
|
|
WO/2024/095922A1 |
Provided is a renal cell aggregate in which the expression level of a transporter gene is improved. An embodiment of the present invention relates to a renal cell aggregate. The aggregate satisfies at least one of the following condition...
|
|
WO/2024/093149A1 |
Provided is a method for preparing tumor-derived cell microparticles by microwave treatment. The method comprises the following steps: 1, taking a Lewis lung carcinoma cell line (LLC), and culturing the cell line in a culture dish for 24...
|
|
WO/2024/093843A1 |
Disclosed are a disease resistance-related protein RCR1, a coding gene thereof, and use thereof. The disease resistance-related protein RCR1 provided by the present invention is a protein set forth in sequence 2. The present invention de...
|
|
WO/2024/097313A1 |
Methods of profiling cells for donor capability with a recipient subject are provided. In particular, methods relating to identifying cells, such as T cells, suitable for making a cell therapy product and administration to a patient (e.g...
|
|
WO/2024/096022A1 |
Provided is an anti-adiponectin antibody or an antibody fragment thereof in which LCDR1 includes an amino acid sequence of SEQ ID NO: 17 or 18, LCDR2 includes an amino acid sequence of SEQ ID NO: 19 or 20, LCDR3 includes an amino acid se...
|
|
WO/2024/097793A1 |
Provided herein is a method of manufacturing recombinant immune cells that comprise a nucleic acid encoding an engineered immune receptor. In some embodiments, the method comprises incubating the cells in vitro with an mTor inhibitor (e....
|
|
WO/2024/036303A3 |
The invention provides a modified HLA-E single chain trimer construct and nucleic acid molecules encoding thereof as well as cells and compositions comprising thereof for increasing the persistence or reducing the clearance of at least o...
|
|
WO/2024/098041A1 |
Various embodiments of the invention provide compositions of tumor infiltrating lymphocytes (TILs) enriched in tumor reactive cells, methods for manufacturing TILs enriched in tumor reactive cells and methods and uses of the provided enr...
|
|
WO/2024/097992A2 |
Provided herein are particles comprising a fusion molecule comprising an adhesion molecule linked to a costimulatory molecule or an activation molecule, as well as vectors, such as lentiviral vectors, comprising the same, cells comprisin...
|
|
WO/2024/096661A1 |
The present invention relates to a method for selectively differentiating and isolating, from pluripotent stem cells, neural crest stem cells comprising axial specification information in the human body. According to the method of the pr...
|
|
WO/2024/096098A1 |
The microfluidic device is equipped with a first chamber that is capable of culturing nerve cells and a channel that extends laterally from the first chamber and is capable of culturing neurites extending from the nerve cells. The channe...
|
|
WO/2024/094076A1 |
Provided are a GIPR binding protein and a use thereof. Specifically provided are a single-domain antibody specifically binding to a glucose-dependent insulinotropic polypeptide receptor, a derived protein thereof, and a pharmaceutical use.
|
|
WO/2024/097314A2 |
Methods of profiling cells for donor capability with a recipient subject are provided. In particular, methods relating to identifying cells, such as T cells, suitable for making a cell therapy product and administration to a patient (e.g...
|
|
WO/2024/097979A1 |
Disclosed are nucleic acids encoding a chimeric antigen receptor comprising an extracellular domain comprising an antigen recognition domain consisting of a fully human single variable heavy (VH) domain that binds a first epitope on B-ce...
|
|
WO/2024/090562A1 |
Provided is a method for producing a glutamate dehydrogenase of which the coenzyme is FAD. Also provided is a FAD-dependent glutamate dehydrogenase having a specified amino acid substitution.
|
|
WO/2024/092026A1 |
Provided herein are methods and compositions for treating a subject having an B cell- associated autoimmune disease, such as lupus nephritis, using T cells engineered with a chimeric antigen receptor that binds CD 19.
|
|
WO/2024/091206A1 |
The invention relates to a cell culture membrane for use during a cell stretching process that stresses the cell to induce mechanical signaling and thus biochemical signals in the cell.
|
|
WO/2024/092001A1 |
The present disclosure provides methods for preventing or treating Alzheimer's disease in a subject, and/or reducing the likelihood or severity of Alzheimer's disease comprising administering to the subject an effective amount of an anti...
|
|
WO/2024/088342A1 |
Described herein are CD24 binding antibodies and fragments thereof.
|
|
WO/2024/087521A1 |
An anti-CD3 antibody and an application thereof. The antibody comprises CDR sequences selected from at least one of the following or amino acid sequences at least 95% identical thereto: heavy chain variable region CDR sequences: SEQ ID N...
|
|
WO/2024/086955A1 |
The present invention relates to a method for obtaining a circulating mitochondria-enriched composition, avoiding platelet activation. This method obtains a circulating mitochondria-enriched composition comprising a high concentration of...
|
|
WO/2024/090514A1 |
A three-dimensional skin model according to one embodiment of the present invention comprises: a first layer including keratinocytes or cells with differentiated keratinocytes; a second layer including dermal fibroblasts; and an intermed...
|
|
WO/2024/091959A1 |
Compositions and method of prevention and treatment for a subject in need comprising drug-resistant natural killer (NK) cells, which are effective for treating cancer when administered in conjunction with cytotoxic therapies. A method of...
|
|
WO/2024/087370A1 |
The present invention relates to the technical field of molecular biology, and provides a preparation method for a eukaryotic expression-based deoxynivalenol full-length antibody and a use of a eukaryotic expression-based deoxynivalenol ...
|
|
WO/2024/089632A1 |
Composition of extracellular vesicles and uses thereof for the treatment of neurological diseases comprising extracellular vesicles derived from stem cells selected from the group consisting of animal stem cells and cell lines. Said extr...
|
|
WO/2024/088309A1 |
Provided are a multispecific antibody binding to GPRC5D and CD3 antigens, an antigen binding molecule thereof, a nucleic acid molecule encoding the multispecific antibody and the antigen binding molecule thereof, a vector containing the ...
|
|
WO/2024/088424A1 |
Provided in the present disclosure is an antibody specifically binding to cytotoxic T lymphocyte-associated antigen-4 (CTLA4), particularly a heavy-chain antibody, and more particularly a single-domain antibody. Also disclosed is the the...
|
|
WO/2024/091907A1 |
Provided herein are compositions, systems, and methods comprising effector proteins for treating HPV infections. These effector proteins may be characterized as CRISPR-associated (Cas) proteins. Various compositions, systems, and methods...
|
|
WO/2024/090893A1 |
The present invention relates to extracellular vesicles (EVs) overexpressing fibronectin fragment protein, and a use for drug delivery thereof. The present invention relates to a method for increasing EV delivery efficiency into cells by...
|
|
WO/2024/088401A1 |
Provided are gene editing systems and methods for reducing cell immunogenicity and reducing graft versus host (GvH) response, or to promote the persistence of therapeutic cells. Also provided are polynucleotides, vectors, cells, kits and...
|
|
WO/2024/091824A1 |
This application relates to stem cell biology and regenerative medicine. Disclosed herein are agents and methods for converting non-chondrocyte cells to chondrocytes or chondrogenic ceils, related cells, related compositions, related pro...
|
|
WO/2024/089629A1 |
An engineered, non-naturally occurring Cas12 protein, CRISPR-Cas system and uses thereof are provided. The engineered, non-naturally occurring novel Cas12 proteins comprise an amino acid sequence selected from SEQ ID NOs: 1-36, a homolog...
|
|
WO/2024/090383A1 |
Provided is a production method of cells into which exogenous mitochondria have been introduced, the production method comprising culturing recipient cells using cell culture equipment in which mitochondria isolated from donor cells are ...
|
|
WO/2024/091902A1 |
The disclosure provides, in various embodiments, non-human animals that comprise a human immune cell engraftment and/or functional human immune system. The disclosure also provides, in various embodiments, methods of generating said non-...
|
|
WO/2024/088325A1 |
The present invention relates to an antibody that specifically binds to CLDN6, and the use thereof.
|
|
WO/2024/087356A1 |
The present invention provides a use of mesenchymal stem cells in preparation of drugs for treating persistent HPV infection. It is surprisingly found in the present invention that mesenchymal stem cells are independently administered, s...
|
|
WO/2024/090702A1 |
The present invention relates to a composition for promoting efficient osteogenic differentiation of adipose-derived stem cells. It has been identified in the present invention that by treating, with FGF2 and/or HGF, in an early stage of...
|
|
WO/2024/092095A1 |
Provided herein are methods and compositions for the diagnosis, prognosis, and treatment of a vascular disease, such as coronary artery disease (CAD), in a subject. In particular, provided are methods and compositions for treating a vasc...
|
|
WO/2024/091944A1 |
What is disclosed herein is a split receptor switch polypeptide comprising an extracellular domain comprising a cytokine binding domain from a first cytokine receptor, wherein the first cytokine receptor is an IL21 receptor, a transmembr...
|
